Pressmeddelande

BioStock: Saniona has started dosing in the SAN711 trial

Cision Publicerad: 08 Oct 08:31

Saniona has initiated dosing of the first subjects with SAN711 in a phase I multiple ascending dose biomarker study, aiming to release topline data by the end of the year. The CEO, Thomas Feldthus, see this as a milestone and a crucial step towards the goal of starting a clinical proof-of-concept study in children with absence seizures next year.
– This study with SAN711 in healthy volunteers offers valuable insights into the appropriate dosing for our phase II trial, helping to ensure positive outcomes.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/10/saniona-has-started-dosing-in-the-san711-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Saniona

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!